Fig. 5

Performance of the third layer of iCAGES. a–c Kaplan–Meier survival curve for 124 TCGA patients with targeted therapy with unknown response whose data were also used in the Rubio-Perez et al. study (testing dataset I). a Red and blue curves represent patients whose treatments do and do not contain iCAGES-predicted first tier drugs, respectively. Red and blue areas represent the 95% confidence interval for the survival curve. b Red and blue curves represent patients whose treatments do and do not contain Rubio-Perez et al.-predicted drugs, respectively. c Red and blue curves represent patients whose treatments do and do not contain DGIdb-predicted drugs. d Number of TCGA patients with targeted therapy with complete response or progressive disease who received correct iCAGES-predicted drugs (blue), DGIdb drugs (gray), Rubio-Perez et al. tier one drugs (orange). e Number of patients used in Rubio-Perez et al. study who can potentially benefit from iCAGES (without pathway component from BioSystem) predicted drugs from three tiers (blue), iCAGES-predicted drugs (green), Rubio-Perez et al.-predicted drugs (orange). Significant advantage of iCAGES compared to other tools is indicated as ***P ≤ 0.0001 and Bonferroni correction (testing dataset III)